• Tags: presbyopia
JJV launches Acuvue Oasys Max-1 MF contact lens for astigmatism
Products

JJV launches Acuvue Oasys Max-1 MF contact lens for astigmatism

Newest addition to the ACUVUE brand is the first and only disposable contact lens for patients with both astigmatism and presbyopia.
Investigators identify new OCT-based biomarker for presbyopic accommodation
Research

Investigators identify new OCT-based biomarker for presbyopic accommodation

Crystalline lens thickness may be a sensitive indicator for presbyopic accommodation.
FDA accepts Tenpoint's Brimochol PF NDA for presbyopia
Pipeline

FDA accepts Tenpoint's Brimochol PF NDA for presbyopia

Fixed-dose-combo eye drop of brimonidine tartrate and carbachol has demonstrated a statistically significant reduction in pupil size up to 10 hours; PDUFA date set for January.
FDA OKs clinical trial on Atia Vision's novel IOL for cataract patients
Pipeline

FDA OKs clinical trial on Atia Vision's novel IOL for cataract patients

IDE approval brings company one step closer toward seeking regulatory clearance for the OmniVu Lens System, a dual-optic IOL.
Allotex names new CEO to lead commercialization of allogeneic corneal tissue technology
Business

Allotex names new CEO to lead commercialization of allogeneic corneal tissue technology

Co-founder Michael Mrochen, PhD, will assume leadership as the startup seeks an IDE for its biocompatible procedure for vision correction.
Tenpoint submits NDA for Brimochol PF for presbyopia
Pipeline

Tenpoint submits NDA for Brimochol PF for presbyopia

The FDA begins a 60-day review period to determine if the submission for the pupil-modulating eye drop is acceptable.
Orasis's QLOSI for presbyopia launches in the US
Products

Orasis's QLOSI for presbyopia launches in the US

Pilocarpine 0.4% provides patients with flexible dosing for up to 8 hours of clear near vision; prescription-based drops are available through two pharmacy partners.
Hoya introduces VisuPro All Day and Flex lenses for young presbyopes
Products

Hoya introduces VisuPro All Day and Flex lenses for young presbyopes

Advanced spectacle lenses target adult patients experiencing an initial gradual loss of vision.
Alcon launches Clareon PanOptix Pro IOL in the US
Products

Alcon launches Clareon PanOptix Pro IOL in the US

With a broad commercial rollout planned for next month, this will be the company’s first presbyopia-correcting IOL available in its Clareon AutonoMe preloaded system.
Tenpoint Therapeutics names veteran executive as first CCO
Business

Tenpoint Therapeutics names veteran executive as first CCO

Carol Kearney to lead company’s efforts to launch and expand global availability of BRIMOCHOL PF for presbyopia.
Opus Genetics receives Fast Track designation, reports phase 3 updates for phentolamine solution
Pipeline

Opus Genetics receives Fast Track designation, reports phase 3 updates for phentolamine solution

VEGA-3 and LYNX-2 trials report completion and near completion of patient enrollment evaluating POS 0.75% for presbyopia and visual loss in low light conditions associated with keratorefractive surgery, respectively.
TECLens raises $9.3M in funding for non-invasive refractive tech
Business

TECLens raises $9.3M in funding for non-invasive refractive tech

The company's corneal CXL-based, non-incisional refractive correction procedure is designed to reshape the corneal for presbyopes and myopes.
Tenpoint reports positive topline data from phase 3 presbyopia eye drop study
Pipeline

Tenpoint reports positive topline data from phase 3 presbyopia eye drop study

With BRIMOCHOL PF meeting its prespecified primary endpoints, the company is planning for a regulatory filing within the first half of 2025.
Tenpoint and Visus Therapeutics merge with plans for ophthalmic therapeutic advancements
Business

Tenpoint and Visus Therapeutics merge with plans for ophthalmic therapeutic advancements

Newly-combined Tenpoint Therapeutics, Ltd includes a pipeline featuring BRIMOCHOL PF, a once-daily eye drop for presbyopia targeting an NDA filing in 2025.
Lenz Therapeutics and Corxel release positive phase 3 presbyopia data from China
Pipeline

Lenz Therapeutics and Corxel release positive phase 3 presbyopia data from China

Statistically significant topline data supports LNZ100’s safety profile just days after the FDA accepts LENZ’s NDA for potential U.S. regulatory approval.
FDA accepts Lenz Therapeutics’ NDA for presbyopia eye drops
Pipeline

FDA accepts Lenz Therapeutics’ NDA for presbyopia eye drops

PDUFA target action date on LNZ100 (1.75% aceclidine) is set for August 2025
FDA approves Bausch + Lomb's en Vista Envy IOL
Products

FDA approves Bausch + Lomb's en Vista Envy IOL

Offering a continuous range of vision with excellent dysphotopsia tolerance, the lens will be initially available on a limited basis.
Orasis secures financing to support US commercial launch of Qlosi
Products

Orasis secures financing to support US commercial launch of Qlosi

With $78 million in Series D financing, the preservative-free pilocarpine solution is one step closer to availability.
J&J expands US rollout of TECNIS Odyssey IOL
Products

J&J expands US rollout of TECNIS Odyssey IOL

Purely refractive presbyopia-correcting lens provides full visual range with minimal visual complaints and higher tolerance to residual refractive errors.
Ocuphire doses first patient in phase 3 presbyopia study on phentolamine solution
Pipeline

Ocuphire doses first patient in phase 3 presbyopia study on phentolamine solution

Already FDA approved as RYZUMVI for reversal of mydriasis, VEGA-3 topline data on POS 0.75% is expected by early 2025.